400 SPECTRUM CENTER DRIVE, IRVINE, CA
Investor Presentation
Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
Reports Second Quarter 2025 Financial Results and Provides Business Updates
Changes in Board, Management or Compensation
Shareholder votes
Reports First Quarter 2025 Financial Results and Provides Business Updates
CG Oncology Reports Key Data on Cretostimogene at AUA Meeting
Annual Report to Security Holders
Q2
Q1
FY 2024
FY 2023
S-3ASR
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Amended Registration Statement for Securities
S-1
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
SEC Staff Correspondence